 |
Throughout this report, results are stated before exceptional items
and goodwill amortisation. Trading profit represents operating profit
before exceptional items and goodwill amortisation and before R&D.
Growth rates are at constant exchange unless otherwise indicated.
| |
|
12
months to 31 Dec 2001 |
|
12
months to 31 Dec 2000
(restated)* |
|
Growth
at constant exchange rate |
|
Growth
at actual exchange rate |
| |
|
£m |
|
£m |
|
% |
|
% |
|
|
Sales |
1,602.5 |
|
1,377.6 |
|
13 |
# |
16 |
|
| • |
Amersham Health |
922.0 |
|
773.9 |
|
13 |
# |
19 |
|
| • |
Amersham Biosciences |
680.5 |
|
603.7 |
|
12 |
|
13 |
|
|
Trading profit |
466.3 |
|
390.2 |
|
11 |
|
20 |
|
|
Research and development |
173.8 |
|
149.0 |
|
16 |
|
17 |
|
|
Operating profit |
292.5 |
|
241.2 |
|
8 |
|
21 |
|
|
Profit before tax |
279.4 |
|
231.2 |
|
9 |
|
21 |
|
|
Earnings per share |
27.2 |
p |
22.5 |
p |
10 |
|
21 |
|
|
Dividend per share |
7.1 |
p |
6.4 |
p |
11 |
|
11 |
*Restated for the introduction of Financial Reporting
Standard 18
#Comparable growth excluding disposed business
|
|
